Key Takeaways
- • Aurenar closed an oversubscribed $5.7 million seed financing round co-led by the Go Red for Women Venture Fund (part of American Heart Association Ventures) and Solas BioVentures, with participation from BJC Health and Kaleida Capital.
- • The company is developing a non-invasive, single-use transauricular vagus nerve stimulation (taVNS) device designed to reduce life-threatening complications in ICU patients by targeting inflammatory response.
- • Capital will fund advancement toward pivotal clinical trials, including final device development, verification and validation testing, and FDA regulatory submissions.
- • Aurenar's platform targets stroke initially but is positioned for expansion to multiple high-acuity indications, with the potential to lower total cost of care in critical care management.
Summary
Aurenar, a St. Louis-based medical device developer, announced the successful close of a $5.7 million oversubscribed seed financing round. The round was co-led by two institutional investors: the Go Red for Women Venture Fund, the venture capital arm of the American Heart Association, and Solas BioVentures. Additional participants included BJC Health and Kaleida Capital, reflecting strong investor confidence in the company's technology platform and market opportunity.
The company is advancing a non-invasive, single-use neuromodulation device based on transauricular vagus nerve stimulation (taVNS) technology. The platform targets a significant clinical need by modulating the body's inflammatory response to reduce severe complications in intensive care unit patients. By addressing the inflammatory cascade that drives adverse outcomes in critical care settings, Aurenar's approach aims to improve patient outcomes while reducing total cost of care—a dual value proposition that resonates with both clinical and payer stakeholders.
The seed capital will support Aurenar's progression toward pivotal clinical trials, a critical milestone for medical device companies. Specifically, proceeds will fund final device development, comprehensive verification and validation testing, and regulatory submissions to the FDA. This pathway positions the company to advance from development stage toward clinical evidence generation required for commercialization.
Aurenar's initial indication is stroke, a high-mortality, high-morbidity condition with significant unmet need in acute care settings. The modular nature of the neuromodulation platform creates expansion opportunities across multiple high-acuity indications beyond stroke, suggesting a scalable commercial model. The participation of American Heart Association Ventures—a mission-aligned investor—alongside traditional venture and healthcare investors underscores both the clinical significance and commercial potential of the technology.
The company is advancing a non-invasive, single-use neuromodulation device based on transauricular vagus nerve stimulation (taVNS) technology. The platform targets a significant clinical need by modulating the body's inflammatory response to reduce severe complications in intensive care unit patients. By addressing the inflammatory cascade that drives adverse outcomes in critical care settings, Aurenar's approach aims to improve patient outcomes while reducing total cost of care—a dual value proposition that resonates with both clinical and payer stakeholders.
The seed capital will support Aurenar's progression toward pivotal clinical trials, a critical milestone for medical device companies. Specifically, proceeds will fund final device development, comprehensive verification and validation testing, and regulatory submissions to the FDA. This pathway positions the company to advance from development stage toward clinical evidence generation required for commercialization.
Aurenar's initial indication is stroke, a high-mortality, high-morbidity condition with significant unmet need in acute care settings. The modular nature of the neuromodulation platform creates expansion opportunities across multiple high-acuity indications beyond stroke, suggesting a scalable commercial model. The participation of American Heart Association Ventures—a mission-aligned investor—alongside traditional venture and healthcare investors underscores both the clinical significance and commercial potential of the technology.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.